CEO Executive AssistantPharma manufacturing scale-up leadership is one of the highest-stakes operational challenges a CEO faces. The window between a positive Phase III readout and commercial launch is finite, the capital commitments are large, and the consequences of delays or quality failures are severe – financially, regulatorily, and reputationally. CEOs who navigate scale-up well understand precisely where their attention belongs and where experienced operators should be left to execute.
The common failure mode is not too little CEO involvement. It is misplaced CEO involvement: excessive engagement in technical detail while strategic decisions about capacity, partnership structure, and risk tolerance go underaligned at the top.
Understanding the CEO’s Role in Manufacturing Scale-Up
Manufacturing scale-up spans process development, tech transfer to commercial facilities, validation, regulatory submission of manufacturing data, and readiness for launch inventory build. Across this arc, a CEO is not a process engineer or a quality systems expert. But a CEO is the person who:
- Sets the risk tolerance for build-ahead inventory before regulatory approval
- Decides whether to manufacture internally or use a CDMO, and at what scale
- Resolves capital allocation conflicts between manufacturing investment and other pipeline priorities
- Communicates with the board and investors on launch readiness timelines
- Owns the relationship with regulatory agencies when manufacturing data forms part of the NDA or BLA
These decisions concentrate in the 18 to 24 months before anticipated approval. This is the period where CEO time allocation in manufacturing needs to be highest, not as a technical supervisor, but as a strategic decision-maker and organizational integrator.
Building the Right Oversight Structure
Appoint a Single Accountable Leader
Manufacturing scale-up benefits from one accountable leader with clear authority across process development, tech transfer, quality, and supply chain. Whether this is your Chief Manufacturing Officer, Head of Technical Operations, or Chief Operating Officer, this person should be your primary interface for manufacturing execution.
Resist the temptation to create a matrix of oversight across multiple leaders when technical problems emerge. Problems that surface during scale-up – yield failures, analytical method discrepancies, vendor capacity constraints – need fast decision-making, not committee review. Your single accountable leader should have the authority and the budget to move quickly, escalating to you only when decisions exceed their mandate.
A clear escalation protocol matters here. Define upfront: what triggers a CEO briefing (cost overrun above a threshold, timeline slip beyond a defined buffer, regulatory query requiring CEO input) and what gets resolved below you. This prevents both under-escalation (surprises) and over-escalation (you spending hours on solvable technical problems).
Manufacturing Readiness Reviews as a Calendar Anchor
Establish a quarterly Manufacturing Readiness Review as a standing calendar item during the scale-up phase. This review, led by your accountable manufacturing leader and supported by quality, regulatory, and supply chain, covers: process performance against targets, tech transfer status, validation milestones, and launch inventory plan versus approval probability.
This 90-minute session keeps you calibrated without requiring you to monitor manufacturing operations week to week. Between reviews, you receive a brief written update (one page or equivalent) flagging any items that have moved materially from the last review.
During the six months closest to anticipated approval, shift this to a monthly cadence. The decisions coming out of pre-launch manufacturing reviews – how much inventory to build, how to respond to a validation failure, how to communicate delays to the commercial team – are high-consequence and time-sensitive.
Capital Allocation: The CEO’s Central Manufacturing Decision
The most consequential manufacturing decision you make during scale-up is capital: how much to invest in capacity before you have regulatory approval, and in what form.
Build-ahead inventory and capital commitments involve real risk. Approval could be delayed by an FDA Complete Response Letter tied to manufacturing data. Commercial demand could come in below forecast. A competitor approval could change the market before you launch. Against these risks, you have the cost of delay: launching weeks or months late against a competitive window is expensive in revenue terms and potentially permanent in market share terms.
This is a CEO-level risk calibration, informed by your regulatory affairs and commercial teams but ultimately owned by you. Develop a clear framework for these decisions: at what confidence level in approval timing do you authorize what level of build-ahead? What is the financial exposure if you build ahead and approval is delayed by six months?
Your Chief Financial Officer and Chief Regulatory Officer need to be in this conversation explicitly, bringing financial modeling on both scenarios. Do not let manufacturing and commercial teams each push for their preferred outcome without a structured CEO-led discussion. This decision is one of the places where your pipeline review cadence process should formally include manufacturing readiness and investment authorization.
Internal Manufacture vs. CDMO: A Decision That Requires CEO Resolution
The make-versus-buy decision for commercial manufacturing is often contested internally. Manufacturing leadership may advocate for internal capacity investment as a strategic capability. Finance may prefer the capital efficiency of CDMO outsourcing. Commercial may have preferences based on launch timeline certainty.
This decision warrants CEO resolution because it has long-term strategic implications: it affects your fixed cost base, your operational leverage, your dependency on external partners, and your ability to control quality and supply continuity. Present both options rigorously, including the supply risk scenarios for each, and make the call. Revisit it only if the underlying assumptions change materially.
If you go the CDMO route, maintain CEO-level awareness of the CDMO relationship at key milestones: contract terms, tech transfer completion, and validation. For a critical product launch, the CDMO relationship at CEO level (not just at the operational level) gives you the ability to escalate and resolve issues that your team cannot move alone.
Quality Culture Starts at the CEO Level
Manufacturing scale-up quality failures are often preceded by cultural signals that quality is being traded against speed. When scale-up timelines are aggressive and the commercial team is pressing for launch readiness, there is organizational pressure to move through quality gates faster than the data supports.
CEOs who make explicit, public statements that quality is non-negotiable – and who back this by not overriding quality holds in the face of commercial pressure – establish a standard that persists through the scale-up process. CEOs who send mixed signals create environments where quality problems get managed rather than resolved.
Your role is not to review batch records or sign off on validation protocols. Your role is to make unmistakably clear that the quality function has authority to slow or stop a process when the data demands it, and that your expectation is that quality issues surface early and honestly rather than being managed quietly until they become FDA findings.
Regulatory Interface During Scale-Up
Manufacturing data is a core component of your NDA or BLA submission. When FDA or EMA raises questions about manufacturing processes, analytical methods, or facility compliance, these queries can affect approval timelines significantly.
Your regulatory affairs team owns the operational response. But your regulatory timeline management as a CEO requires awareness of manufacturing-related queries and, in some cases, direct engagement. When a major facility inspection is scheduled, when a manufacturing-related Complete Response Letter arrives, or when a pre-approval inspection finding requires executive commitment, the CEO’s direct communication to the agency – through appropriate channels – carries weight that staff-level correspondence does not.
Know your agency relationships before you need them. Introductory meetings with FDA’s Office of Pharmaceutical Quality are appropriate for companies in late-stage development, even if they feel premature. The relationship capital you build before a crisis is what allows you to navigate one effectively.
Preparing for Launch Inventory and Commercial Coordination
Manufacturing scale-up does not end at regulatory approval. The handoff to commercial operations – coordinating inventory deployment, specialty distribution networks, and patient services – requires manufacturing to be deeply integrated with commercial planning in the six months pre-launch.
As CEO, your job is to ensure this integration is happening at the organizational level, not to coordinate it yourself. Set the expectation early that manufacturing and commercial are joint owners of the launch inventory plan. Review the alignment between the two in your quarterly Manufacturing Readiness Reviews. The specific failure mode to watch for is commercial teams that have not made their demand assumptions explicit, leaving manufacturing to build inventory against a forecast that has not been stress-tested.
Conclusion
Pharma manufacturing scale-up leadership at the CEO level is a discipline of strategic clarity: knowing which decisions are yours, building the organizational infrastructure to make good decisions quickly, and maintaining the quality culture that protects the asset you are bringing to market. The executives who navigate this well are not those with the most technical depth. They are the ones who ask the right questions, make high-stakes resource decisions with rigor, and create organizations where quality and speed are pursued as complements rather than trade-offs.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.